Compare Crispr Therapeutics AG (CRSP) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tractor Supply Co — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Tractor Supply Co trades at $33.7 (market cap $17.44B). The key difference: Tractor Supply Co is far larger — about 3.6× Crispr Therapeutics AG's market cap, and Tractor Supply Co pays a 2.87% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Tractor Supply Co for 89 Days on average.
| CRSP | TSCO | |
|---|---|---|
Market Cap | $4.88B | $17.44B |
Volume | 2,861,747 | 10,598,723 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.97 | $56.37 |
52-Week Low | $44.34 | $29.14 |
Typical Hold Time | 77 Days | 89 Days |
Enterprise Value | $3.30B | $23.76B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Tractor Supply (TSCO) trades at $33.48, up 2.95% today, showing resilience after recent earnings misses. The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates consistent revenue growth reaching $15.52B in 2025, with healthy profitability metrics including 36.46% gross margin and 39.51% ROE. Recent corporate developments include new distribution center openings and ongoing community investment initiatives.
The investment outlook remains cautiously optimistic with a $36.76 consensus price target representing 9.8% upside potential. Key opportunities include the company's 17-year dividend growth streak and strategic expansion, while risks center on consecutive earnings misses and institutional selling pressure. The balanced analyst coverage (48% buy, 50% hold) reflects uncertainty about near-term performance amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
